High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
about
A review of the medical treatment of primary sclerosing cholangitis in the 21st centuryPathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementTreatment of autoimmune liver disease: current and future therapeutic options.Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis.Recent advances in the development of farnesoid X receptor agonistsCurrent research on the treatment of primary sclerosing cholangitis.Approach to a patient with elevated serum alkaline phosphatase.Baseline Ultrasound and Clinical Correlates in Children with Cystic FibrosisRecent insights in primary sclerosing cholangitis.The overlap syndromes of autoimmune hepatitis.Primary Sclerosing Cholangitis: Current and Future Management Strategies.A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis.Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis.Role of the microbiota and antibiotics in primary sclerosing cholangitis.Recent developments in the management of idiopathic cholestatic liver diseaseVedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.Short-term prognostic factors for primary sclerosing cholangitis.Gastrointestinal Manifestations of Cystic Fibrosis.Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis
P2860
Q26771816-0503C0B7-972F-4324-8E1E-DEF47793C867Q27015831-CFFDC682-4B12-4CB0-9D67-D90136A72474Q34342199-519D299E-2120-4259-B3E0-54DE1CDB3B92Q34403316-30F1C4D9-82BE-400E-8C95-9A055597E226Q34464043-44963D70-2301-4A9F-B477-B4149BDDDBF1Q35066561-3EEB2DEA-0EF6-470B-8D64-9D6E6F8ECEA3Q35926418-A6F45E33-2BE6-44AD-B379-9C5D2CB3F439Q36101665-30EEC2B5-6CA3-4EBC-A4CA-4B4C7E0298FCQ38019989-6B302F3D-813C-4842-9BE9-602ED51F2C57Q38037392-C7D68770-62B0-4B3D-9591-A2986398A3DAQ38107484-8430F36E-B083-4EB7-AB1F-02EEFBFE630EQ38584285-718F1130-C171-4C60-B0A2-850AB29AD94CQ38833243-19567308-6851-4717-ACA6-447E194FED25Q39177947-E80E8A46-21CE-4C4A-A9DC-0A9202EE97A1Q42174395-473CBA0E-54A6-4E3E-AD95-38E7CD562E15Q42406650-A2F7FCDF-9762-47C6-BDBB-8A623D9D7A6AQ48151874-3C7819DE-F0CB-499E-8630-18BD105ED5C5Q48253693-F74BE569-869A-41FB-BA06-E05C7DA4C1FCQ53627194-3F317379-6529-43B2-B8C0-7202B50A88C3Q58551479-9FD26B7F-FDFE-4699-88DC-808A6BAB127C
P2860
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@en
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@nl
type
label
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@en
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@nl
prefLabel
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@en
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@nl
P2093
P2860
P1476
High-dose ursodeoxycholic acid ...... rimary sclerosing cholangitis.
@en
P2093
A A Gossard
A C DeCook
A S Befeler
K D Lindor
K V Kowdley
P2860
P304
P356
10.1111/J.1365-2036.2011.04863.X
P407
P577
2011-09-29T00:00:00Z